Literature DB >> 27660244

Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.

Laura C Sullivan1, Teresa S Chavera1, Raehannah J Jamshidi1, Kelly A Berg2, William P Clarke1.   

Abstract

Opioid receptors expressed by peripheral pain-sensing neurons are functionally inactive for antinociceptive signaling under most basal conditions; however, tissue damage or exposure to inflammatory mediators (e.g., bradykinin) converts these receptors from a nonresponsive state to a functionally competent state. Here we tested the hypothesis that the basal, nonresponsive state of the mu- and delta-opioid receptors (MOR and DOR, respectively) is the result of constitutive receptor activity that activates desensitization mechanisms, resulting in MOR and DOR receptor systems that are constitutively desensitized. Consistent with our previous findings, under basal conditions, neither the MOR agonist [d-Ala2,N-MePhe4,Gly-ol5]-enkephalin nor the DOR agonist [d-Pen2,5]-enkephalin, inhibited prostaglandin E2 (PGE2)-stimulated cAMP accumulation in peripheral sensory neurons in culture (ex vivo) or inhibited PGE2-stimulated thermal allodynia in the rat hind paw in vivo. Prolonged treatment with naloxone induced MOR and DOR responsiveness both in vivo and ex vivo to a similar magnitude as that produced by bradykinin. Also similar to bradykinin, the effect of naloxone persisted for 60 minutes after washout of the ligand. By contrast, prolonged treatment with 6β-naltrexol, did not induce functional competence of MOR or DOR but blocked the effect of naloxone. Treatment with siRNA for β-arrestin-2, but not β-arrestin-1, also induced MOR and DOR functional competence in cultured peripheral sensory neurons. These data suggest that the lack of responsiveness of MOR and DOR to agonist for antinociceptive signaling in peripheral sensory neurons is due to constitutive desensitization that is likely mediated by β-arrestin-2.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27660244      PMCID: PMC5118646          DOI: 10.1124/jpet.116.232835

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  55 in total

Review 1.  Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery.

Authors:  Richard A Bond; Ad P Ijzerman
Journal:  Trends Pharmacol Sci       Date:  2006-01-06       Impact factor: 14.819

Review 2.  Defining and characterizing drug/compound function.

Authors:  Terry Kenakin; Michael Williams
Journal:  Biochem Pharmacol       Date:  2013-08-15       Impact factor: 5.858

3.  Dual regulation of δ-opioid receptor function by arachidonic acid metabolites in rat peripheral sensory neurons.

Authors:  Laura C Sullivan; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2015-01-30       Impact factor: 4.030

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  Regulation of opioid receptors in rat sensory neurons in culture.

Authors:  J J Chen; J Dymshitz; M R Vasko
Journal:  Mol Pharmacol       Date:  1997-04       Impact factor: 4.436

6.  Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.

Authors:  Laura M Bohn; Robert J Lefkowitz; Marc G Caron
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

7.  Regulation of serotonin 5-HT2C receptors by chronic ligand exposure.

Authors:  Mark G Devlin; Nicola J Smith; Olivia M Ryan; Elizabeth Guida; Patrick M Sexton; Arthur Christopoulos
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

8.  Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.

Authors:  Benjamin Chanrion; Clotilde Mannoury la Cour; Sophie Gavarini; Mathieu Seimandi; Laurent Vincent; Jean-François Pujol; Joël Bockaert; Philippe Marin; Mark J Millan
Journal:  Mol Pharmacol       Date:  2007-12-14       Impact factor: 4.436

9.  Rapid modulation of micro-opioid receptor signaling in primary sensory neurons.

Authors:  Kelly A Berg; Amol M Patwardhan; Teresa A Sanchez; Yamille M Silva; Kenneth M Hargreaves; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2007-03-08       Impact factor: 4.030

10.  Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2.

Authors:  Hoa Lam; Matthew Maga; Amynah Pradhan; Christopher J Evans; Nigel T Maidment; Tim G Hales; Wendy Walwyn
Journal:  Mol Pain       Date:  2011-04-12       Impact factor: 3.395

View more
  5 in total

Review 1.  Dynamic Opioid Receptor Regulation in the Periphery.

Authors:  Nathaniel A Jeske
Journal:  Mol Pharmacol       Date:  2019-02-05       Impact factor: 4.436

2.  Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.

Authors:  Joshua C Zamora; Hudson R Smith; Elaine M Jennings; Teresa S Chavera; Varun Kotipalli; Aleasha Jay; Stephen M Husbands; Alex Disney; Kelly A Berg; William P Clarke
Journal:  Pharmacol Res Perspect       Date:  2021-12

Review 3.  Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.

Authors:  Kelly A Berg; William P Clarke
Journal:  Int J Neuropsychopharmacol       Date:  2018-10-01       Impact factor: 5.176

Review 4.  Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.

Authors:  Wolfgang Sadee; John Oberdick; Zaijie Wang
Journal:  Molecules       Date:  2020-09-11       Impact factor: 4.411

5.  Effects of intracerebroventricularly administered opioid peptide antagonists on tissue glycogen levels in rats after exercise

Authors:  Ayşe Şebnem İlhan; Şevin Güney; Sibel Dincer
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.